chlorpromazine
Trade name: Thorazine
Approved
Sep 18, 1957
Chlorpromazine is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Chlorpromazine has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Chlorpromazine has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity. Chlorpromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects). Additionally, Chlorpromazine is a weak presynaptic inhibitor of Dopamine reuptake, which may lead to (mild) antidepressive and antiparkinsonian effects. Chlorpromazine has being marketed under the trade names Thorazine and Largactil among others. Chlorpromazine is used for treating certain mental or mood disorders (eg, schizophrenia), the manic phase of manic-depressive disorder, anxiety and restlessness before surgery, the blood disease porphyria, severe behavioral and conduct disorders in children, nausea and vomiting, and severe hiccups. — NCATS
Clinical trial activity
18 trials · 39 clinical orgs · 51 marketing orgs
Earliest trial started Dec 1, 1994 (NCT00169039)
Timeline
1950s
- Sep 18, 1957
Earliest FDA Approval
- Sep 18, 1957
GlaxoSmithKline — NDA Secondary Org
1970s
- Mar 16, 1972
Lederle — Marketing Organization
- Mar 16, 1972
American Cyanamid — Marketing Organization
- Jan 3, 1973
Sandoz — Marketing Organization
- Feb 13, 1974
Watson Pharmaceuticals — Marketing Organization
- Feb 13, 1974
Dr. Reddy's Laboratories — Marketing Organization
- May 6, 1974
Teva — Marketing Organization
- Jul 9, 1974
Upsher-Smith Laboratories — Marketing Organization
- Mar 1, 1976
Fosun — Marketing Organization
- Mar 1, 1976
Allied Pharmaceutical Services — Marketing Organization
- Mar 1, 1976
Saptalis Pharmaceuticals — Marketing Organization
- Dec 8, 1977
Abraxis — Marketing Organization
- Feb 6, 1978
Lumara Health — Marketing Organization
1980s
- Aug 13, 1980
Parke-Davis — Marketing Organization
- Aug 13, 1980
Warner Lambert — Marketing Organization
- Nov 7, 1980
Actavis — Marketing Organization
- Nov 10, 1980
Alpharma — Marketing Organization
- Feb 4, 1981
Wockhardt — Marketing Organization
- Dec 14, 1981
Vanguard — Marketing Organization
- Jun 28, 1982
Puracap Pharmaceutical — Marketing Organization
- Sep 16, 1982
West-Ward Pharmaceutical — Marketing Organization
- Apr 27, 1983
Cycle Pharmaceuticals Ltd. — Marketing Organization
- Apr 27, 1983
Hikma — Marketing Organization
- Apr 15, 1988
Marsam Pharmaceuticals — Marketing Organization
1990s
- Jan 26, 1999
Pharmaceutical Associates — Marketing Organization
2000s
- Jan 1, 2001
Earliest Phase 3 Sponsor(trial)
2010s
- Jan 1, 2016
Cycle Pharmaceuticals Ltd. — Earliest Phase 1 Sponsor(trial)
- Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
- Sep 10, 2018
Amneal Pharmaceuticals — Marketing Organization
2020s
- Jan 17, 2020
Zydus Discovery DMCC — Marketing Organization
- Jul 7, 2020
Aurobindo Pharma — Marketing Organization
- Jul 7, 2020
Eugia Pharma — Marketing Organization
- Aug 31, 2020
Appco Pharma — Marketing Organization
- Aug 31, 2020
Mayne Pharma — Marketing Organization
- Aug 31, 2020
Somerset Pharmaceuticals — Marketing Organization
- Oct 26, 2020
Sun Pharmaceuticals — Marketing Organization
- Jan 22, 2021
Lannett Company, Inc. — Marketing Organization
- Mar 23, 2021
Glenmark Pharmaceuticals — Marketing Organization
- Jun 2, 2021
Genus Oncology, LLC — Marketing Organization
- Nov 29, 2021
Enaltec — Marketing Organization
- Nov 29, 2021
ZAMEER PHARMS — Marketing Organization
- Nov 29, 2021
Chartwell Pharmaceuticals — Marketing Organization
- Jan 27, 2022
MSN Laboratories — Marketing Organization
- Jul 13, 2023
Lupin — Marketing Organization
- Jul 18, 2023
Alembic — Marketing Organization
- Sep 24, 2024
Deva Holding A.S. — Marketing Organization
- Oct 4, 2024
Gland Pharma Ltd — Marketing Organization
- Nov 18, 2024
Aspiro — Marketing Organization
- Dec 10, 2024
THINQ Pharma CRO Ltd. — Marketing Organization
- Oct 10, 2025
Rubicon Research — Marketing Organization
Indications
Approved for
Studied for
- Affective Disorders, Psychotic · Phase 1
- Aggression · Phase 4
- Antipsychotic Agents · Phase 2/Phase 3
- Anxiety · Phase 4
- Bipolar Disorder · Phase 4
- Colonic Neoplasms · Phase 1/Phase 2
- COVID-19 · Phase 3
- Delirium · Phase 2/Phase 3
- Depression · Phase 1
- Drugs, Investigational · Phase 1
- Epilepsy · Phase 2/Phase 3
- General Surgery · Phase 1
- Glioblastoma · Phase 2
- Healthy Volunteers · Phase 1
- Hiccup · Phase 1
- Ischemic Stroke · Phase 1
- Nausea · Phase 1
- Neonatal Abstinence Syndrome · Phase 3
- Neoplasm Metastasis · Phase 2/Phase 3
- Neoplasms · Phase 2/Phase 3
- Porphyria, Acute Intermittent · Phase 1
- Psychiatry · Phase 4
- Psychotic Disorders · Phase 4
- Schizophrenia · Phase 4
- Tetanus · Phase 1
Mechanism of action
- Serotonin 2a (5-HT2a) receptorANTAGONIST
HTR2A antagonist
- D2-like dopamine receptorANTAGONIST
D2-like dopamine receptor antagonist
Approval history
- approvedSep 18, 1957
Chemistry & pharmacology
SMILES
CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21- Mol. weight
- 318.87 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral, Topical
- Availability
- Prescription Only
Oral
Yes
Parenteral
Yes
Topical
Yes
Sources
- ChEMBLCHEMBL71 ↗
- WikipediaChlorpromazine ↗
- NCATSU42B7VYA4P ↗
- ChEMBLCHEMBL1713 ↗
Also known as
- 2-chloropromazine
- 3-(2-chloro-10h-phenothiazin-10-yl)-n,n-dimethyl-1-propanamine
- 3-(2-chloro-10h-phenothiazin-10-yl)-n,n-dimethyl-1-propanamine
- 3-(2-chlorophenothiazin-10-yl)-n,n-dimethyl-propan-1-amine
- 3-(2-chlorophenothiazin-10-yl)-n,n-dimethyl-propan-1-amine
- aminazine
- aminazine
- chloractil
- chloractil
- chlorazine
- chlorazine
- chlordelazin
- chlorderazin
- chlorderazin
- chlorderazin
- chloropromazine
- chloropromazine
- chlorpromados
- chlorpromados
- chlorpromazine
- chlorpromazine
- chlorpromazine
- chlorpromazine
- chlorpromazine
- chlorpromazine
- chlorpromazine
- chlorpromazine
- chlorpromazine
- chlorpromazine
- chlorpromazine
- chlorpromazine hcl
- chlorpromazine hcl
- chlorpromazine hcl
- chlorpromazine hibenzate
- chlorpromazine hydrochloride
- chlorpromazine hydrochloride
- chlorpromazine hydrochloride
- chlorpromazine hydrochloride
- chlorpromazine hydrochloride
- chlorpromazine hydrochloride intensol
- chlorpromazine hydrochloride intensol
- chlorpromazine phenolphthalinate
- chlorpromazine phenolphthalinate
- chlorpromazine tannate
- chlorpromazine tannate
- chlorpromazinum
- chlorpromazinum
- clorpromazina
- clorpromazina
- contomin
- contomin
- contomin
- cpz
- cpz
- elmarin
- elmarin
- largactil
- largactil
- largactil fte
- megaphen
- megaphen
- n-(3-dimethylaminopropyl)-3-chlorophenothiazine
- n-(3-dimethylaminopropyl)-3-chlorophenothiazine
- promapar
- promapar
- rimazine
- sonazine
- sonazine
- thorazine
- thorazine
- thorazine
- thorazine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06663631 | Phase 1 | Nov 30, 2024 | Capital Medical University, Linyi People's Hospital |
| NCT05431595 | Phase 2/Phase 3 (Phase 3) | Dec 30, 2022 | State of Texas, University of Texas at Houston |
| NCT05433402 | Phase 1/Phase 2 (Phase 2) | Jul 20, 2022 | Sadat City University |
| NCT05190315 | Phase 1 | Jan 28, 2022 | University of Iowa |
| NCT04354805 | Phase 1/Phase 2 (Phase 2) | May 31, 2020 | Cairo University |
| NCT04366739 | Phase 3 | Apr 29, 2020 | Centre Hospitalier St Anne, Service Hospitalo-Universitaire - GHU PARIS Psychiatrie & Neurosciences, University of Paris |
| NCT04224441 | Phase 2 | Dec 15, 2019 | Carlo Besta Neurological Institute, Istituto Oncologico Veneto IRCCS, ISTITUTO REGINA ELENA |
| NCT06154434 | Phase 1 | Dec 6, 2018 | Chonbuk National University, Whanin Pharmaceutical Company |
| NCT03639558 | Phase 4 | Aug 28, 2018 | Croix-Rousse Hospital, Lyon, University of Nottingham |
| NCT03183310 | N/A | Jul 1, 2017 | Katholieke Universiteit Leuven |
| NCT03021486 | Phase 2/Phase 3 (Phase 3) | Jun 5, 2017 | National Institutes of Health (NIH), University of Texas at Houston |
| NCT02943213 | Phase 1 | Nov 1, 2016 | Cycle Pharmaceuticals Ltd., Parexel |
| NCT01404364 | N/A | Jan 1, 2010 | Hospital Governador Celso Ramos |
| NCT00882518 | Phase 3 | Apr 1, 2009 | AstraZeneca, Jiao Tong University |
| NCT00654576 | Phase 4 | Feb 1, 2005 | Capital Medical University, Central South University, Chongqing Medical University, Guangzhou Medical University, Henan Medical University, Hunan Mental Hospital, Jiangxi Mental Hospital, Jiao Tong University, Nanjing Medical University, Sichuan University |
| NCT00202293 | Phase 4 | Oct 1, 2001 | Melbourne Health, University of Lausanne |
| NCT02810782 | Phase 3 | Jun 1, 2001 | University of Zurich |
| NCT00169039 | Phase 4 | Dec 1, 1994 | Dartmouth University, Harvard University, National Institute of Mental Health (NIMH), Novartis |
Organizations
Research & Development (39)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Capital Medical University | Academic/Hospital | 2 | 1 | 2 | 2005 |
| Jiao Tong University | Academic/Hospital | 2 | 0 | 2 | 2005 |
| University of Texas at Houston | Academic/Hospital | 2 | 2 | 1 | 2017 |
| AstraZeneca | For profit | 1 | 1 | 1 | 2009 |
| Cairo University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Carlo Besta Neurological Institute | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Central South University | Academic/Hospital | 1 | 1 | 1 | 2005 |
| Centre Hospitalier St Anne | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Chonbuk National University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Chongqing Medical University | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Croix-Rousse Hospital, Lyon | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Cycle Pharmaceuticals Ltd. | For profit | 1 | 1 | 1 | 2016 |
| Dartmouth University | Academic/Hospital | 1 | 0 | 1 | 1994 |
| Guangzhou Medical University | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 1994 |
| Henan Medical University | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Hospital Governador Celso Ramos | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Hunan Mental Hospital | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Istituto Oncologico Veneto IRCCS | Academic/Hospital | 1 | 0 | 1 | 2019 |
| ISTITUTO REGINA ELENA | Academic/Hospital | 1 | 1 | 1 | 2019 |
Marketing (59)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Abbott | For profit | MKTG | — |
| Abraxis | For profit | MKTG | Dec 8, 1977 |
| Actavis | For profit | MKTG | Nov 7, 1980 |
| Alembic | For profit | MKTG | Jul 18, 2023 |
| Allied Pharmaceutical Services | For profit | MKTG | Mar 1, 1976 |
| Alpharma | For profit | MKTG | Nov 10, 1980 |
| American Cyanamid | For profit | MKTG | Mar 16, 1972 |
| American Home Products | For profit | MKTG | — |
| Amneal Pharmaceuticals | For profit | MKTG | Sep 10, 2018 |
| Appco Pharma | For profit | MKTG | Aug 31, 2020 |
| Aspiro | For profit | MKTG | Nov 18, 2024 |
| Aurobindo Pharma | For profit | MKTG | Jul 7, 2020 |
| Chartwell Pharmaceuticals | For profit | MKTG | Nov 29, 2021 |
| Cycle Pharmaceuticals Ltd. | For profit | MKTG | Apr 27, 1983 |
| Deva Holding A.S. | For profit | MKTG | Sep 24, 2024 |
| Dr. Reddy's Laboratories | For profit | MKTG | Feb 13, 1974 |
| Enaltec | For profit | MKTG | Nov 29, 2021 |
| Eugia Pharma | For profit | MKTG | Jul 7, 2020 |
| Fosun | For profit | MKTG | Mar 1, 1976 |
| Genus Oncology, LLC | For profit | MKTG | Jun 2, 2021 |
| Gland Pharma Ltd | For profit | MKTG | Oct 4, 2024 |
| Gland Pharma Ltd | For profit | SYN | Oct 4, 2024 |
| GlaxoSmithKline | For profit | NDA2 | Sep 18, 1957 |
| Glenmark Pharmaceuticals | For profit | MKTG | Mar 23, 2021 |
| Hikma | For profit | MKTG | Apr 27, 1983 |
| Hikma | For profit | SYN | Apr 27, 1983 |
| Lannett Company, Inc. | For profit | MKTG | Jan 22, 2021 |
| Lederle | For profit | MKTG | Mar 16, 1972 |
| Lumara Health | For profit | MKTG | Feb 6, 1978 |
| Lupin | For profit | MKTG | Jul 13, 2023 |
| MSN Laboratories | For profit | MKTG | Jan 27, 2022 |
| Marsam Pharmaceuticals | For profit | MKTG | Apr 15, 1988 |
| Mayne Pharma | For profit | MKTG | Aug 31, 2020 |
| Mylan | For profit | MKTG | — |
| Parke-Davis | For profit | MKTG | Aug 13, 1980 |
| Pharmaceutical Associates | For profit | MKTG | Jan 26, 1999 |
| Puracap Pharmaceutical | For profit | MKTG | Jun 28, 1982 |
| Rubicon Research | For profit | MKTG | Oct 10, 2025 |
| Sandoz | For profit | MKTG | Jan 3, 1973 |
| Saptalis Pharmaceuticals | For profit | MKTG | Mar 1, 1976 |
| Smith, Kline & French | For profit | NDA | — |
| Somerset Pharmaceuticals | For profit | MKTG | Aug 31, 2020 |
| Sun Pharmaceuticals | For profit | MKTG | Oct 26, 2020 |
| Sun Pharmaceuticals | For profit | SYN | Oct 26, 2020 |
| THINQ Pharma CRO Ltd. | For profit | MKTG | Dec 10, 2024 |
| Teva | For profit | MKTG | May 6, 1974 |
| Teva | For profit | MKTG | Oct 25, 2021 |
| Upsher-Smith Laboratories | For profit | MKTG | Jul 9, 1974 |
| Upsher-Smith Laboratories | For profit | SYN | Jul 9, 1974 |
| Vanguard | For profit | MKTG | Dec 14, 1981 |
| Warner Lambert | For profit | MKTG | Aug 13, 1980 |
| Watson Pharmaceuticals | For profit | MKTG | Feb 13, 1974 |
| West-Ward Pharmaceutical | For profit | MKTG | Sep 16, 1982 |
| West-Ward Pharmaceutical | For profit | SYN | Jul 25, 1974 |
| Wockhardt | For profit | MKTG | Feb 4, 1981 |
| ZAMEER PHARMS | For profit | MKTG | Nov 29, 2021 |
| Zydus Discovery DMCC | For profit | MKTG | Jan 17, 2020 |
| Zydus Discovery DMCC | For profit | SYN | Mar 13, 2024 |
| Zydus Discovery DMCC | For profit | SYN | Jan 17, 2020 |